



ScinoPharm Management Presentation

TWSE 1789

May 2, 2012



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation is ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.



Table of Content

Overview of ScinoPharm

Financial & Operation Results

China Market

Business Outlook

Q&A






Overview of ScinoPharm

Company Overview


- Maintain dominant position in Specialty APIs for generic market. Established strong presence in US/EU generic market, some channeled through Indian generic companies. Aggressively developing Japanese and Chinese markets
- Developed more than 50 generic APIs with 16 launched. Filed 41 DMFs in US (595 DMFs WW), leader in supplying oncology injectable APIs with 19 US DMFs
- 70+ NCE CRAMs projects, with 5 in phase III with NDA filing in 2-3 years & 3 already launched. The only company in Asia supplying API for multiple NCEs for commercial



ScinoPharm Changshu



Construction completed



ScinoPharm Changshu vs Tainan

■ Identical



- Same facility size (6.6 hectare)
- API R&D capabilities (R&D staff >100 people)
- International GMP standards
- Advanced EHS standards
- Global registration (incl. China)
- Successful GMP inspections by regulated markets (incl. US)
- Production of high potent oncological and other APIs
- Generic APIs and CRO/CMO services

■ Complementary

- Tainan focuses on high potency; Changshu on mid-low potency
- Tainan targets on global markets; Changshu on Chinese potential
- Changshu to serve more Chinese customers
- Changshu to provide intermediates to Tainan
- Changshu to serve more CRAM business



ScinoPharm leads in Oncology



Financial & Operation Results

P&L - Consolidated

NT\$MM, except EPS	Q1,'12 (reviewed)	Q4,'11 (audited)	Q1,'11 (reviewed)	QoQ	YoY
Net Sales	971	1,130	796	-14%	22%
Gross Profit	523	597	370	-12%	41%
<i>Gross margin</i>	<i>54%</i>	<i>53%</i>	<i>47%</i>		
Operating Expense	(239)	(251)	(180)	-5%	33%
Operating Income	284	346	190	-18%	49%
<i>Operating margin</i>	<i>29%</i>	<i>31%</i>	<i>24%</i>		
Other Rev.(Exp.)	7	(26)	(10)	27%	70%
Net Income after Tax	247	320	144	-22%	61%
<i>Net margin after tax</i>	<i>25%</i>	<i>28%</i>	<i>18%</i>		
EPS (after tax)	0.39	0.51	0.24	-24%	63%

EPS are calculated based on weighted average number of outstanding shares



Balance Sheet- Consolidated

NT\$MM	2012/03/31 (reviewed)		2011/03/31 (reviewed)	
Cash and Cash Equivalents	3,236	33%	1,989	27%
Accounts Receivable	740	8%	597	8%
Inventories	1,801	18%	1,424	19%
Long-Term Investments	150	2%	218	3%
Fixed Assets	3,291	34%	2,833	38%
Total Assets	9,689	100%	7,425	100%
Current Liabilities	849	9%	568	8%
L-T Liabilities and Others	29	0%	26	0%
Stockholders' Equities	8,811	91%	6,831	92%





Cash Flows- Consolidated

NT\$MM	Q1, 2012 (reviewed)	Q1, 2011 (reviewed)
Cash and cash equivalents at beginning of year	3,294	1,908
Cash flows from operating activities	147	218
CAPEX	(171)	(125)
Other Investing activities	34	(12)
Cash flows from financing activities	-	-
Cash and cash equivalents at end of year	3,236	1,989




Sales by Business




Sales by Indications

2011Q1



2012Q1






China – Emerging Market for the World


China: the top 3 pharma market WW

- In 2010, China fast grew to the 3rd largest pharmaceutical market globally, only next to USA and Japan
- China market will continue to grow at a CAGR of 22% from US\$ 41 billion in 2010 to US\$ 125 billion in 2015
- ScinoPharm Changshu (China) has been established to catch the opportunities

2010 Total Market 856 Bn



2015 Total Market 1095 Bn



New GMP in China has raised the standards

- **New GMP conforms international standards and emphasizes the facility sophistication**
 - Strict requirements on air pressure isolation in high potent areas
 - Detailed rules on A/C, purified water, packaging systems
 - Rigid equipment qualifications in DQ/IQ/OQ/PQ stages
- **SFDA focuses on the quality control by facility designs**
 - Requires high efforts in preventing cross contamination
 - Need more facility space and CAPEX for compliance



Impacts of China's New GMP

- To consolidate pharma industry, enhance its capability, a new version of GMP was issued on March 1, 2011 with a grace period of 5 years
- 500+ pharma companies in China might not survive
- Many formulation companies are looking for new-GMP compliant API providers, like ScinoPharm.
- ScinoPharm is building a new-GMP compliant API plant in Changshu and is the first one to meet the high bar.



Product portfolio fits China's demands

Rank	Therapeutic indication	2010 China Market Share	ScinoPharm's API candidates
1	Anti-infective	23.7%	3 candidates
2	Anti-cancer	10.3%	30 candidates, focus area
3	Cardio-vascular	8.2%	4 candidates
4	Metabolic	7.1%	5 candidates
5	CNS	1.7%	6 candidates

Source: Chinese Pharmaceutical Market 2012-2022, Visiongain, Jun2011



Anti-cancer drugs in China

- Top 20 anti-cancer drugs in China weigh about 74% in value out of total anti-cancer drugs, **ScinoPharm has 9 products ready**

Ranking in China	Drug	Market value (RMB bln)
2	Docetaxel	1.54
3	Capecitabine	1.14
4	Paclitaxel	1.10
8	Pemetrexed	0.76
9	Gemcitabine	0.66
16	Anastrozole	0.30
18	Letrozole	0.27
19	Irinotecan	0.26
20	Bortezomib	0.16

- Oncological drug market grew by 30% in 2010

Other top drugs include


- 3 bio drugs
- 8 old/oral drugs – low entry barrier

Source: *healthoo.com* May2011



Peer comparison

– number of oncological DMFs in China



***SPT will proceed to submitting DMF applications to the SFDA**



ScinoPharm Penetrates China Market by:

- **API sales**

Sell APIs made by Taiwan and Changshu plants to local or foreign formulation companies in China

- **Co-development with local formulation firms**

Partner with Chinese formulation companies to integrate from APIs to formulations to penetrate oncology market, currently dominated by Big Pharmas

- **Drug imports**

Cooperate with our existing global customers to introduce their high-quality drug products to Chinese market



Business Outlook

2012 Product Launch Plan

API	Region	Indications	Brand Marketer	Regional Sales	WW Sales
Argatroban	US	Antithrombotic, Anticoagulant	GSK	\$US 139MM*	\$US 205MM*
Galantamine HBr	EU	Alzheimer's disease	Janssen	\$US 314MM*	\$US 527MM*
Modafinil	US	Antinarcolepsy	Cephalon	\$US 1,078MM*	\$US 1,182MM*
Riluzole	EU	ALS	Sanofi Aventis	\$US 100MM*	\$US 224MM*
Anastrozole	JP	Breast Cancer	Astra Zeneca	\$US 270MM*	\$US 1,109MM*
Levonorgestrel	JP	Oral Contraceptive	Bayer AG	\$US 85MM*	\$US 2,326MM*
SPT 1024	US + EU	Obesity	Confidential	\$US 633MM**	NDA

Source: * Newport & IMS Data
 ** Thomson Reuter



Outlook

- Sustain Our Current Leadership Position

Continue developing small molecule oncological injectable APIs and expand into other areas with high technology barriers including Peptides and Biopharmaceutical

- Expand Presences in China

Expansion of API business to timely capture the Chinese market facing increasingly stringent GMP requirement

- Japanese Market Penetration

Establishing strategic partnerships with major pharma companies in Japan and expect to market total 6 products in 2012

- Vertical Integration

With synergy of our API business, expand into high-entry-barrier formulation business to maximize ROI





Brand Quality with Asian Advantages

www.scinopharm.com

